Compounds > bisindolylmaleimide i
Page last updated: 2024-10-23

bisindolylmaleimide i and Hormone-Dependent Neoplasms

bisindolylmaleimide i has been researched along with Hormone-Dependent Neoplasms in 1 studies

bisindolylmaleimide I: a bis(indolyl)maleimide

Research Excerpts

ExcerptRelevanceReference
"Treatment of androgen responsive prostate cancer cells with dihydrotestosterone leads to a rapid and reversible activation of mitogen-activated protein kinases MAPKs (also called extracellular signal-regulated kinases or Erks)."1.30Rapid signalling by androgen receptor in prostate cancer cells. ( Becker, M; Cato, AC; Klocker, H; Mink, S; Peterziel, H; Schonert, A, 1999)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Peterziel, H1
Mink, S1
Schonert, A1
Becker, M1
Klocker, H1
Cato, AC1

Other Studies

1 other study available for bisindolylmaleimide i and Hormone-Dependent Neoplasms

ArticleYear
Rapid signalling by androgen receptor in prostate cancer cells.
    Oncogene, 1999, Nov-04, Volume: 18, Issue:46

    Topics: Adenocarcinoma; Androgen Antagonists; Cell Nucleus; Cytoplasm; Dihydrotestosterone; DNA-Binding Prot

1999